Asia-Pacific · Research
International consensus guideline on curative-intent care for de novo metastatic NPC
A guideline from 54 experts in 18 countries or regions sets out 32 recommendations, including when curative-intent multimodality treatment should be offered in de novo metastatic nasopharyngeal carcinoma.
Background
In the past, patients diagnosed with metastatic nasopharyngeal carcinoma were considered incurable and received only palliative care1. The combination of potent systemic therapy and local treatment for both locoregional and metastatic disease has enabled some patients to achieve long‑term survival1.
How the guideline was developed
The guideline was formulated through consensus among 54 specialists from 46 institutions across 18 countries or regions, and it received endorsement from 17 oncology bodies1. It sets out 32 recommendations spanning seven clinical domains1:
- 29 strong recommendations, based on high-quality evidence or ≥80% agreement (consensus)1
- 3 conditional recommendations (67-79% agreement)1
Key recommendation
The guideline recommends offering curative‑intent treatment to medically fit patients with up to three metastatic lesions in no more than two organs, either at diagnosis or after systemic therapy response1. The recommended approach is multimodal, combining immunotherapy and chemotherapy, radiotherapy to locoregional disease, treatment targeting the metastases, and maintenance treatment1.
Purpose
This guideline serves as a practical tool for standardizing care and highlights important gaps in evidence that warrant further investigation1.
References
- Guo QJ, Liu Q, Bossi P, Bonomo P, Colevas AD, Lee NY, et al. Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations. Lancet Oncol. 2026;27(11):e557-e570. doi:10.1016/S1470-2045(26)00347-5. PMID: 42933448. PubMed
